MedPageToday -- ORLANDO -- Cancer recurrence and death occurred significantly more often in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs), data from a retrospective cohort review showed. ESA treatment also was associated with a briefer progression-free survival (PFS) and reduced overall survival, Rodney P. Rocconi, MD, of the University of South Alabama in Mobile, reported here at the Society of Gynecologic Oncology meeting.
